Due Diligence

We combine deep knowledge of corporate transactions with sector-specific expertise in intellectual property, regulatory compliance, and the particular dynamics of life sciences companies. Because we advise life sciences companies on these areas on a day-to-day basis, we know what the risks look like in practice, where they tend to be hidden, and what they mean for the relationship or deal at hand.

We conduct legal and regulatory due diligence tailored specifically to life sciences transactions and collaborations. Our review covers regulatory compliance and approval status under the Medical Device Regulation (MDR), the In Vitro Diagnostics Regulation (IVDR), and the Medicines Act, (pre)clinical data obligations, pharmacovigilance requirements, and post-market surveillance risks. On the IP side, we review licensing arrangements and identify encumbrances or restrictions that could affect the commercial viability of the transaction or partnership. Data protection compliance forms another core element of our review, encompassing GDPR obligations relating to health data processing and consent frameworks. We also assess corporate structures and key commercial agreements, including shareholding arrangements, corporate governance documents, existing obligations, and assignment restrictions that are relevant to the deal or partnership. Where we identify risks, we advise on how to reflect them in the structure through targeted warranties, indemnities and measures.